$14.44
+0.35 (+2.48%)
Open$13.67
Previous Close$14.09
Day High$14.44
Day Low$13.50
52W High$69.97
52W Low$11.60
Volume—
Avg Volume441.4K
Market Cap224.61M
P/E Ratio—
EPS$-14.25
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+182.1% upside
Current
$14.44
$14.44
Target
$40.74
$40.74
$28.14
$40.74 avg
$50.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.95M | 84.57M | 86.26M |
| Net Income | -226,648,175 | -20,699,385 | -25,319,011 |
| Profit Margin | -946.2% | -24.5% | -29.4% |
| EBITDA | -230,544,559 | -24,990,141 | -25,196,528 |
| Free Cash Flow | — | -20,292,095 | -20,848,476 |
| Rev Growth | — | +3.2% | +20.0% |
| Debt/Equity | — | 0.58 | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |